21.11.2017
- European pharmaceutical industry heavyweights Novartis and Bayer are challenging a proposal by parts of the UK’s National Health Service (NHS) to allow patients with wet age...
17.12.2014
- Bayer's Eylea (VEGF Trap-Eye) is not more effective than its competitor Lucentis to treat patients with diabetic macular edema, the German Institute for Quality and Efficiency in...
16.09.2014
- Roche's cancer drug Avastin as a cheaper treatment for wet age-related macular degeneration (wAMD), a leading cause of blindness in the elderly, does not appear to increase deaths...
06.01.2014
- Bayer HealthCare has hit a stumbling block in the sales campaign for its new drug Eylea (aflibercept), or VEGF Trap-Eye, recommended for treatment of age-related wet macula...
27.07.2012
- A U.S. Food and Drug Administration panel on Thursday recommended two drugs for combating different forms of vision loss that can lead to blindness among a range of adults...
